NEW YORK, April 21, 2009 (GLOBE NEWSWIRE) -- Roy Jacobs & Associates is investigating potential shareholder claims in connection with Broadcom Corp.'s offer to purchase Emulex Corp. (NYSE:ELX) for $9.25 per share and Emulex apparent unwillingness to entertain the offer or seek to maximize shareholder value. Rather it has been reported that Emulex has adopted a poison pill defense to prevent the Company from being acquired, and as a possible tool to entrench management in violation of their fiduciary duties, which will prevent shareholders from realizing top value for their shares, which could materially exceed Broadcom's current offer.
If you held Emulex shares as of April 20, 2009 and you are interested in discussing your rights free of charge, please contact Roy L. Jacobs. Mr. Jacobs will be glad to personally speak with you.